| Literature DB >> 990059 |
K D Schulz, W Geiger, E Del Pozo, K H Lose, H J Künzig, I Lancranjan.
Abstract
Five volunteers with normal ovarian cycles received oral doses of 2 X 2.5 mg or 3 X 2.5 mg bromocriptin (CB 154)/day respectively. The treatment started at the onset of menstruation and lasted on complete cycle. In addition to the decrease of prolactin secretion, a reduction of plasma progesterone concentrations during the corpus luteum phase was demonstrated. This fall of progesterone seemed to be preferentially due to bromocriptin-induced hypoprolactinaemia and not to direct ovarian effects of the drug.Entities:
Mesh：
Substances：
Year: 1976 PMID： 990059 DOI： 10.1007/bf00667138
Source DB: PubMed Journal: Arch Gynakol ISSN： 0003-9128